RFA Treatment for Benign Thyroid Nodules
“We are now one of the only centers in the Southwest and Westcoast to offer this new procedure for patients.”
– Melanie GoldFarb, M.D.
Saint John’s Cancer Institute is renowned research facility dedicated to advanced therapeutics, translational sciences, and best medical practices. We promote robust fellowship programs and clinical trials, collaborating with industry and academic partners worldwide.Read More
Saint John’s Cancer Institute (SJCI) is a pioneer in drug discovery, therapeutics, and clinical trials. SJCI conducted the research that established the Sentinel Lymph Node Biopsy under the late Dr. Donald L. Morton, which has become the standard of lymph node care for melanoma and breast cancer worldwide. Today, our patients continue to have access to innovative treatments, therapeutics, and trials. We are at the forefront of understanding the biology of cancer as well as expanding treatment for under-served communities.Learn More
“We have had prior evidence that it may have anti-cancer activity in patients with early-stage prostate cancer.”
– Przemyslaw Twardowski, M.D.
“This team has a tremendous opportunity to create solutions that can be used as national models for integrated colorectal cancer outreach and screening.”
– Anton Bilchik, M.D.
The Breast Surgical Oncology Fellowship at the Saint John’s Cancer Institute provides a diverse and comprehensive exposure to the multidisciplinary aspects of breast cancer care and benign breast disease over a one-year time period with a potential second year for continuation of clinical or basic science research.LEARN MORE ABOUT THIS FELLOWSHIP
With a longstanding history of excellence in multidisciplinary cancer care and education, the Saint John’s Cancer Institute continues to be a leader in training the next generation of leaders in the field of surgical oncology.Learn more about this fellowship
As pioneers in translational studies on “liquid biopsies” involving circulating tumor cells in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms regulating solid tumor as well as pharmacogenomics and immunogenomic based prediction of response to therapy.Learn more about this fellowship
This training program focuses on endonasal endoscopic and keyhole surgical approaches, neuro-endoscopy, pituitary tumor management and multimodality neuro-oncology treatments.Learn more about this fellowship
Przemyslaw W. Twardowski, M.D., and his colleagues, have published a new study in the New England Journal of Medicine, which demonstrates significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments. Based on the results of that study on 5/19/2020 Food and Drug Administration (FDA) granted approval of olaparib, providing a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test.
The department of Translational Neurosciences studied ANG1005, a novel taxane derivative, which consists of 3 paclitaxel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Read the publication to learn the results.
This is the first study to assess the utility of subtypes of T cells as prognostic markers in patients with colorectal peritoneal carcinomatosis, which may play a role in patients with low-volume disease. The purpose of this study is to evaluate immune profiles of patients with peritoneal carcinomatosis and their correlation with overall survival (OS).